Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Invest New Drugs ; 38(5): 1257-1271, 2020 10.
Article in English | MEDLINE | ID: mdl-31838735

ABSTRACT

Twelve multi-functional pyrrolizidinones, indolizidinones and pyrroliazepinones were prepared from formal aza-[3 + 2] and aza-[3 + 3] cycloadditions of five- to seven-membered heterocyclic enaminones as diverse ambident electrophiles. The antitumor activity of these alkaloid-like compounds was investigated through an initial screening performed on human glioblastoma multiform (GBM) cell lines (GL-15, U251), on murine glioma cells line (C6) and on normal glial cells. Of the compounds tested, the new pyrrolo[1,2a]azepinone, [ethyl (3-oxo-1,2-diphenyl-6,7,8,9-tetrahydro-3H-pyrrolo[1,2a]azepin-9a(5H)-yl)acetate] or (Compound-13) exhibited selective cytotoxic effects on GBM-temozolomide resistant cells. Compound-13 exerted dose-dependent cytotoxic activity by promoting arrest of cells in the G0/G1 phase of the cell cycle in the first 24 h. The apoptotic effect observed was in a time-dependent manner. Anti-migratory effect promoted by the treatment with compound-13 was also observed. Moreover, healthy mixed glial cell cultures from rat brain exhibited no cytotoxicity effect upon exposure to compound-13. Thus, the present study paves the way for the use of compound-13 as novel antitumor scaffold candidate for glioma cell therapy.


Subject(s)
Antineoplastic Agents/pharmacology , Azabicyclo Compounds/pharmacology , Brain Neoplasms/drug therapy , Glioblastoma/drug therapy , Animals , Apoptosis/drug effects , Cell Cycle/drug effects , Cell Movement/drug effects , Cell Survival/drug effects , Cells, Cultured , Drug Design , Drug Resistance, Neoplasm/drug effects , Humans , Rats, Wistar , Temozolomide/pharmacology , Wound Healing/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...